KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $248.5 million.

  • Novavax's Operating Expenses rose 1369.74% to $248.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $757.2 million, marking a year-over-year decrease of 3619.09%. This contributed to the annual value of $931.1 million for FY2024, which is 3993.79% down from last year.
  • Latest data reveals that Novavax reported Operating Expenses of $248.5 million as of Q3 2025, which was up 1369.74% from $138.2 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Operating Expenses ranged from a high of $1.0 billion in Q4 2021 and a low of $138.2 million during Q2 2025
  • For the 5-year period, Novavax's Operating Expenses averaged around $446.2 million, with its median value being $393.7 million (2023).
  • As far as peak fluctuations go, Novavax's Operating Expenses soared by 239623.58% in 2021, and later tumbled by 6372.36% in 2023.
  • Over the past 5 years, Novavax's Operating Expenses (Quarter) stood at $1.0 billion in 2021, then tumbled by 42.58% to $601.3 million in 2022, then fell by 21.02% to $474.9 million in 2023, then tumbled by 53.8% to $219.4 million in 2024, then increased by 13.25% to $248.5 million in 2025.
  • Its last three reported values are $248.5 million in Q3 2025, $138.2 million for Q2 2025, and $151.1 million during Q1 2025.